Is combination therapy indicated for invasive fungal infections? Yes and no

Current Opinion in Infectious Diseases

Volumn 19, Issue 4, 2006, Pages 357-359

  Montoya, José G ^a,b   Rosso, Fernando ^a,b,c  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUNDACIÓN VALLE DEL LILI   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90; HUMAN MONOCLONAL ANTIBODY; ITRACONAZOLE; RECOMBINANT GAMMA INTERFERON;

ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDIASIS; DRUG INDICATION; EDITORIAL; FUNGAL MENINGITIS; HUMAN; MYCOSIS; NONHUMAN; PROGNOSIS;

ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MYCOSES; RANDOMIZED CONTROLLED TRIALS;

EID: 33745630079     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000235162.63055.c6     Document Type: Editorial

References (19)

1. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 (Suppl 3):S188-S224.
2. Rex JH, Wingard JR, Wenzel R, et al. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. Clin Infect Dis 2004; 39 (Suppl 4):S165-S169.
3. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology (Huntingt) 2004; 18:24-29.
4. Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005; 65:1461-1480.
5. Sobel JD. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin Infect Dis 2004; 39 (Suppl 4):S224-S227.
6. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707-717.
7. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-251.
8. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-326.
9. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
10. Marr KA, Boeckh M, Kim HW. Reply to Cesaro and Visintin. Clin Infect Dis 2005; 40:1075-1076.
11. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301:126-131.
12. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15-21.
13. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767.
14. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-2191.
15. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003; 36:1221-1228.
16. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42:1404-1413.
17. Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005; 103:2334-2337.
18. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41:1448-1452.
19. Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28:82-92.